Nano Targeting & Therapy Biopharma Inc. (NTT Biopharma) is an innovative biotech company specializing in the development of silica nanocarrier platforms for optimized drug delivery. Through their patented mesoporous silica nanoparticle (MSN) technology, NTT Biopharma creates nanomedicine products designed to address complex drug delivery issues in diseases such as brain cancer, immunotherapy, and ocular diseases.

NTT Biopharma has a diverse pipeline of nano-formulated NCE/505(b)(2) products and also seeks partnerships with pharmaceutical companies to enhance drug delivery solutions. They offer contract research services for novel formulation development, manufacturing process optimization, and preliminary efficacy evaluation studies at the non-GMP quality level. Additionally, NTT Biopharma can be a trusted long-term partner throughout the drug development process.

Their mission is to provide better solutions for drug delivery, leveraging the unique properties of MSN nanomaterials combined with bioactive ingredients to develop safer, more convenient, and effective nano-pharmaceutical products for various disease states.

Founded by esteemed leaders in the field, including Chairman & Co-Founder Hardy Chan, PhD, and Co-Founders Chung-Yuan Mou, PhD, and Yun Yen, MD, PhD, NTT Biopharma brings together decades of experience and expertise in biotechnology, chemistry, and medicine.

Contact NTT Biopharma at TEL: +866 2 23657579 or email [email protected]. They are located at Rm. 307,3F.,Building B, No.18, Siyuan St., Zhongzheng Dist., Taipei City 10087, Taiwan (R.O.C.).